I. Introduction to NAFLD and its Progression

Non-alcoholic fatty liver disease (NAFLD) has emerged as a global health concern, affecting approximately 25% of the world's population. In Hong Kong, the prevalence is notably high, with studies indicating that around 30% of adults suffer from NAFLD, mirroring trends in other urbanized regions. The disease spectrum ranges from simple steatosis to non-alcoholic steatohepatitis (NASH), which can progress to advanced fibrosis, cirrhosis, and even hepatocellular carcinoma. The economic burden is substantial, with healthcare costs for NAFLD-related complications in Hong Kong estimated to exceed HKD 1 billion annually.

Liver fibrosis is a critical determinant of NAFLD prognosis. Patients with significant fibrosis (stage F2 or higher) face a markedly increased risk of liver-related morbidity and mortality. A longitudinal study in Hong Kong revealed that NAFLD patients with advanced fibrosis (F3-F4) had a 5-year liver-related mortality rate of 12%, compared to just 1% for those with mild fibrosis (F0-F1). This underscores the importance of accurate fibrosis staging in clinical management. Traditional risk stratification tools like the FIB-4 index often lack precision in intermediate-risk groups, creating a pressing need for more reliable diagnostic methods such as .

II. as a Diagnostic Tool for NAFLD

has revolutionized NAFLD management by providing a non-invasive, real-time assessment of liver stiffness and controlled attenuation parameter (CAP), which correlates with steatosis severity. Unlike liver biopsy—the historical gold standard— eliminates risks of bleeding, pain, and sampling variability while delivering immediate results. In Hong Kong hospitals, the procedure typically takes less than 10 minutes and requires no special patient preparation beyond a 2-hour fast.

Clinical studies have established validated cut-off values for fibrotouch in NAFLD populations:

Serial FibroTouch examinations enable clinicians to monitor disease progression objectively. A Hong Kong cohort study demonstrated that patients showing a >15% increase in liver stiffness over 12 months had a 3-fold higher risk of hepatic decompensation. This dynamic assessment capability makes FibroTouch invaluable for tailoring follow-up intervals and therapeutic strategies.

III. FibroTouch Accuracy in Assessing Treatment Response

Lifestyle interventions remain first-line therapy for NAFLD, and FibroTouch provides quantitative metrics to evaluate their effectiveness. A 2023 Hong Kong study showed that patients achieving ≥7% weight loss through dietary modification and exercise exhibited a median liver stiffness reduction of 2.4 kPa (p<0.01) on FibroTouch, correlating with histologic improvement in 78% of cases. The technology's ability to detect subtle changes (as small as 0.5 kPa) makes it superior to conventional ultrasound for monitoring therapeutic responses.

For pharmacological therapies, FibroTouch serves as an objective endpoint in clinical trials. In a recent evaluation of GLP-1 receptor agonists, FibroTouch-measured stiffness decreased by 1.8 kPa after 48 weeks of treatment, paralleling reductions in NAFLD Activity Score (NAS) on biopsy. The device's high intra-observer concordance (ICC=0.92 in Hong Kong validation studies) ensures reliable longitudinal assessment—a crucial advantage over subjective histopathologic interpretations.

IV. Integrating FibroTouch with Other Diagnostic Modalities

Combining FibroTouch with serum biomarkers creates a powerful diagnostic algorithm. The MAST (Modality Algorithm for Staging Tool) protocol, implemented at Queen Mary Hospital Hong Kong, sequentially applies:

• FIB-4 score for initial risk stratification
• FibroTouch for intermediate-risk patients (FIB-4 1.3-2.67)
• MRI-PDFF for discordant cases

This approach reduced unnecessary biopsies by 62% while maintaining 94% diagnostic accuracy for advanced fibrosis. Correlation studies show FibroTouch agrees with biopsy in 86% of cases when using the ≥9.5 kPa threshold for F3 fibrosis. Notably, the device performs exceptionally well in obese patients (BMI>30)—a population where transient elastography often fails—with successful measurement rates exceeding 95% in Hong Kong's NAFLD registry.

V. Future Directions

Ongoing research aims to enhance FibroTouch accuracy through artificial intelligence. A collaborative project between Hong Kong Polytechnic University and Peking Union Medical College is developing deep learning algorithms that integrate FibroTouch parameters with clinical variables (e.g., HbA1c, platelet count) to predict 3-year fibrosis progression risk with 89% AUC. Another innovation involves shear wave elastography mapping, which provides spatial distribution of liver stiffness—addressing the sampling limitation of single-point measurements.

The ultimate goal is personalized risk prediction. Preliminary data from the Hong Kong NAFLD Prediction Model (HK-NPM) combines FibroTouch results with genetic polymorphisms (PNPLA3, TM6SF2) to stratify patients into:

• Low-risk: annual monitoring
• Intermediate-risk: 6-month FibroTouch + biomarker check
• High-risk: immediate hepatology referral

Such advancements position FibroTouch as the cornerstone of precision medicine in NAFLD management, transforming how we detect, monitor, and treat this increasingly prevalent condition.

Posted by: jkaihkkyyet博客 at 06:42 AM | No Comments | Add Comment
Post contains 739 words, total size 7 kb.